Actively Recruiting
Vascular Signature Mapping of Brain Tumor Genotypes
Led by Leiden University Medical Center · Updated on 2025-03-10
180
Participants Needed
2
Research Sites
189 weeks
Total Duration
On this page
Sponsors
L
Leiden University Medical Center
Lead Sponsor
E
Erasmus Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
A glioma is a primary brain tumor in adults that is characterized by a highly variable, but overall poor survival. The optimal timing of treatment is in part determined by the expected biological behavior of the tumor. At present the expected biological behavior, determined by the tumor genotype, can only be determined by tissue analysis, which requires brain surgery. Non-invasive and improved diagnostic methods are sought to obtain insight into the molecular profile of the tumor and the expected biological behavior to avoid surgery performed solely for diagnostic purposes. Vascularization is an important aspect of the biological behavior of a primary brain tumor. Tumor vascularization characteristics can be assessed by Magnetic Resonance Imaging (MRI), but with the currently available technology this can only be achieved with unacceptably long scan times. In this proposal, the investigators will develop and optimize a novel MRI protocol to gather a large set of quantitative vascularization parameters within an acceptable scan time. The hypothesis is that from such a 'vascular signature' the tumor genotype can be inferred by means of machine learning.
CONDITIONS
Official Title
Vascular Signature Mapping of Brain Tumor Genotypes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients scheduled for brain MRI with contrast injection as part of the clinical diagnostic procedure
- Patients diagnosed with suspected glioma scheduled for brain MRI as part of the clinical diagnostic procedure
- Patients with suspected or confirmed glioma referred for tumor biopsy or resection
- Age 18 years or older
- Signed informed consent
You will not qualify if you...
- Contraindications for MRI examination
- Reduced kidney function due to risk of nephrogenic systemic fibrosis from gadolinium contrast
- Pregnancy
- Participation in a clinical protocol requiring scanning during contrast agent injection (for cohort 1)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Leiden University Medical Center
Leiden, Netherlands, 2333ZA
Not Yet Recruiting
2
Erasmus University Medical Center
Rotterdam, Netherlands, 3000CA
Actively Recruiting
Research Team
D
Daniëlle van Dorth, MSc
CONTACT
M
Matthias JP van Osch, Prof Dr Ir
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here